Ivan Borbath

28.2k total citations · 4 hit papers
155 papers, 6.3k citations indexed

About

Ivan Borbath is a scholar working on Oncology, Epidemiology and Surgery. According to data from OpenAlex, Ivan Borbath has authored 155 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Oncology, 71 papers in Epidemiology and 41 papers in Surgery. Recurrent topics in Ivan Borbath's work include Neuroendocrine Tumor Research Advances (62 papers), Pancreatic and Hepatic Oncology Research (60 papers) and Lung Cancer Research Studies (44 papers). Ivan Borbath is often cited by papers focused on Neuroendocrine Tumor Research Advances (62 papers), Pancreatic and Hepatic Oncology Research (60 papers) and Lung Cancer Research Studies (44 papers). Ivan Borbath collaborates with scholars based in Belgium, France and United States. Ivan Borbath's co-authors include Juan W. Valle, Pascal Hammel, F. Huguet, Catherine Lombard‐Bohas, Eric Van Cutsem, Dieter Hörsch, Philippe Ruszniewski, Jean‐Luc Raoul, Éric Raymond and Denis Smith and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Ivan Borbath

149 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

2011 1.8k citations Éric Raymond, Laëtitia Dahan et al. profile →
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib

2016 685 citations F. Huguet, Jean‐Luc Van Laethem et al. profile →
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2016 471 citations Juan W. Valle, Ivan Borbath et al. Annals of Oncology profile →
Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

2022 174 citations Pierre H. Deprez, Dermot O’Toole et al. profile →

Peers

Countries citing papers authored by Ivan Borbath

Since Specialization

Citations

This map shows the geographic impact of Ivan Borbath's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivan Borbath with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivan Borbath more than expected).

Fields of papers citing papers by Ivan Borbath

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ivan Borbath. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivan Borbath. The network helps show where Ivan Borbath may publish in the future.

Co-authorship network of co-authors of Ivan Borbath

This figure shows the co-authorship network connecting the top 25 collaborators of Ivan Borbath. A scholar is included among the top collaborators of Ivan Borbath based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ivan Borbath. Ivan Borbath is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10—Precision Medicine) 2025 ·ESMO Open ·David Malka, Ivan Borbath, Andre Lopes, (unknown), (unknown), Timon Vandamme, Juan W. Valle, James Wason, (unknown), (unknown), (unknown), Julien Edeline, John Bridgewater	1
2	Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study. 2024 ·Journal of Clinical Oncology ·Richard S. Finn, Masatoshi Kudo, Ivan Borbath, Julien Edeline, Stéphane Cattan, Hans Van Vlierberghe, Chris Verslype, Daniel H. Palmer, Per Stål, Sadahisa Ogasawara, (unknown), Mark Karwal, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, (unknown), Ken Hatogai, Abby B. Siegel, Ann‐Lii Cheng, Jean‐Luc Van Laethem	2
3	Neuroendocrine tumors in the stomach: An epidemiological analysis of Belgian Cancer Registry data 2010–2019 2024 ·Journal of Neuroendocrinology ·(unknown), (unknown), (unknown), Anne Hoorens, (unknown), Pieter‐Jan Cuyle, Timon Vandamme, Ivan Borbath, Pieter Demetter, Nancy Van Damme, Liesbet Van Eycken, Chris Verslype, Karen Geboes	3
4	Long‐term clinical and radiological outcomes of endoscopic ultrasound‐guided radiofrequency ablation of benign insulinomas 2023 ·Clinical Endocrinology ·(unknown), Ivan Borbath, Pierre H. Deprez, (unknown), Dominique Maiter, (unknown)	7
5	Belgian guidelines for pathology reporting of neuroendocrine neoplasms of the pancreaticobiliary and gastrointestinal tract. Initialized by the Belgian Group of Digestive Oncology (BGDO) and supported by the BGDO, the BSP (Belgian Society of Pathology) and the BCR (Belgian Cancer Registry) 2023 ·Acta Gastro Enterologica Belgica ·Anne Hoorens, Ivan Borbath, Timon Vandamme, Chris Verslype, Pieter Demetter, (unknown), (unknown), Nancy Van Damme, Karen Geboes	1
6	Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria 2022 ·Current Oncology ·P. Dabadie, Stéphan Walrand, Renaud Lhommel, Michel Hesse, Ivan Borbath, François Jamar	3
7	ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors 2022 ·Journal of Neuroendocrinology ·Ivan Borbath, Ulrich‐Frank Pape, Pierre H. Deprez, Detlef K. Bartsch, Martyn Caplin, Massimo Falconi, Rocio García‐Carbonero, Simona Grozinsky‐Glasberg, Robert T. Jensen, Rudolf Arnold, Philippe Ruszniewski, Christos Toumpanakis, Juan W. Valle, Dermot O’Toole, (unknown)	13
8	The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms 2022 ·European Journal of Cancer ·Ivan Borbath, Rocio García‐Carbonero, (unknown), Paula Jiménez‐Fonseca, Ángel Castaño, (unknown), Eva Sedláčková, Attila Kollár, Emanuel Christ, Gregory Kaltsas, Beata Kos‐Kudła, Sebastian Maasberg, Chris Verslype, Ulrich‐Frank Pape	18
9	Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study 2022 ·European Journal of Cancer ·Côme Lepage, (unknown), Astrid Lièvre, (unknown), Laëtitia Dahan, David Tougeron, Christos Toumpanakis, (unknown), Catherine Lombard‐Bohas, Ivan Borbath, Romain Coriat, Thierry Lecomte, Rosine Guimbaud, Caroline Pétorin, Jean-Louis Legoux, Pierre Michel, J.Y. Scoazec, Denis Smith, Thomas Walter	13
10	VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial 2021 ·Annals of Oncology ·Robin Kate Kelley, Thomas Yau, Ann‐Lii Cheng, Ahmed O. Kaseb, Shukui Qin, Andrew X. Zhu, Stephen L. Chan, Wattana Sukeepaisarnjaroen, В. В. Бредер, Gontran Verset, Edward Gane, Ivan Borbath, (unknown), Philippe Merle, Fawzi Benzaghou, Kamalika Banerjee, Saswati Hazra, Jonathan W. Fawcett, Lorenza Rimassa	48
11	Exploratory analysis based on tumor location of REACHIN, a randomized, double-blinded, placebo-controlled phase 2 trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for advanced/metastatic biliary tract tumors 2019 ·Annals of Oncology ·Anne Demols, Ivan Borbath, Marc Van den Eynde, (unknown), Marc Peeters, Raphaël Maréchal, (unknown), J. Goeminne, Stéphanie Laurent, Stéphane Holbrechts, Marianne Paesmans, Jean‐Luc Van Laethem	2
12	Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3) 2018 ·Neuroendocrinology ·Halfdan Sørbye, Éric Baudin, Ivan Borbath, Martyn Caplin, Jie Chen, Jarosław B. Ćwikła, Andrea Frilling, Ashley Grossman, Gregory Kaltsas, Aldo Scarpa, Staffan Welin, Rocio García‐Carbonero, (unknown)	65
13	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology - Diagnosis and Prognostic Stratification 2017 ·Neuroendocrinology ·Aurel Perren, Anne Couvelard, Jean‐Yves Scoazec, (unknown), Ivan Borbath, Gianfranco Delle Fave, Vera Gorbounova, David J. Gross, Ashley Grossman, Robert T. Jensen, Matthew H. Kulke, Kjell Öberg, Guido Rindi, Halfdan Sørbye, Staffan Welin, (unknown)	165
14	Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up breakdown → 2016 ·Annals of Oncology ·Juan W. Valle, Ivan Borbath, Shahid A. Khan, F. Huguet, Thomas Gruenberger, Dirk Arnold	471
15	Randomized Controlled Phase 2 Study (RCT) with Tivantinib in pre-treated hepatocellular carcinoma(HCC): Efficacy, Safety, and MET-analysis 2012 ·Hepatology ·Ivan Borbath	1
16	Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET) 2012 ·Pancreas ·Aaron I. Vinik, Eric Van Cutsem, Patricia Niccoli, Jean‐Luc Raoul, Yung‐Jue Bang, Ivan Borbath, Catherine Lombard‐Bohas, Juan W. Valle, Peter Metrakos, Denis Smith, Jen‐Shi Chen, Dieter Hoersch, Daniel Castellano, Hagen F. Kennecke, Joel Picus, Guy van Hazel, Shem Patyna, Dongrui R. Lu, Richard C. Chao, Éric Raymond	4
17	Updated Overall Survival Data From a Phase III Study of Sunitinib Vs. Placebo in Patients With Advanced, Unresectable Pancreatic Neuroendocrine Tumour (NET) 2011 ·European Journal of Cancer ·Juan W. Valle, Patricia Niccoli, Jean‐Luc Raoul, (unknown), Ivan Borbath, Eric Van Cutsem, Rickard Sandin, Dongmei Lu, Shem Patyna, (unknown)	2
18	Optimizing specimen collection and laboratory procedures reduces the non‐diagnostic rate for endoscopic ultrasound‐guided fine‐needle aspiration of solid lesions of the pancreas 2011 ·Cytopathology ·Birgit Weynand, Ivan Borbath, (unknown), Hubert Piessevaux, (unknown)	17
19	Large spectrum of liver vascular lesions including high prevalence of focal nodular hyperplasia in patients with hereditary haemorrhagic telangiectasia: the Belgian Registry based on 30 patients 2010 ·European Journal of Gastroenterology & Hepatology ·R Brenard, (unknown), Pierre Deltenre, Jean Henrion, Stéphane De Maeght, Yves Horsmans, Ivan Borbath, (unknown), (unknown), Sven Francque, Thomas Sersté, Christophe Moreno, Hans Orlent, (unknown), Jan Lerut, Christine Sempoux	39
20	Phase III, Randomized, Double-blind Trial of Sunitinib Versus Placebo in Patients With Progressive, Well-differentiated Pancreatic Islet Cell Tumours 2009 ·Annals of Oncology ·Éric Raymond, Ivan Borbath, Jean‐Luc Raoul, Patricia Niccoli, (unknown), Catherine Lombard‐Bohas, Peter Metrakos, Dongmei Lu, C. Blanckmeister, A Vinik	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact